Thailand Diabetes Care Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 152.23 Million |
| Market Size (2029) | USD 173.23 Million |
| CAGR (2024 - 2029) | 3.80 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Thailand Diabetes Care Drugs Market Analysis
The Thailand Diabetes Care Drugs Market size is estimated at USD 152.23 million in 2024, and is expected to reach USD 173.23 million by 2029, growing at a CAGR of 3.80% during the forecast period (2024-2029).
The healthcare system was significantly disturbed and pressured during each phase of rapid COVID-19 infection. Several countries, notably the Thai government, introduced home isolation or a home quarantine program to avert healthcare collapse and to ameliorate inadequate healthcare resources. Between July 2021 and October 2021, COVID-19 illness cases in Thailand increased to around 20,000-25,000 cases per day, posing difficulty in treating COVID-19 infection in hospitals. Previous research revealed the viability of a COVID-19 home monitoring program employing telemedicine to reduce the gap in treatment during a healthcare worker shortage in multiple countries. These programs monitored the intensity of symptoms and informed patients to seek additional treatment if necessary.
During COVID-19, there was a shortage of hospital capacity, and a home isolation system was set up. Thailand's government introduced diabetes self-management education and support (DSMES, glycemic management via telemedicine, and outcomes in home-isolated patients with COVID-19 infection. In August 2022, The National Research Council of Thailand (NRCT) introduced a breathalyzer prototype that can detect those infected with COVID-19 with 97% accuracy.
In terms of medicines, the insulin category commands a sizable market share. Over 100 million people worldwide use insulin, including all persons with Type 1 diabetes and 10% to 25% of people with Type 2 diabetes. Insulin production is extremely sophisticated, and only a few manufacturers are on the market. As a result, there is fierce rivalry among these producers, who continually strive to satisfy patients' demands by providing the highest-quality insulin.
Thailand Diabetes Care Drugs Market Trends
Oral-Anti Diabetes Drugs Segment is Having the Highest Market Share in Current Year
The Oral-Anti Diabetes Drugs segment is expected to increase with a CAGR of over 5 % during the forecast period, mainly due to the demand from the Type-1 diabetes population, which was more than 0.4 million by the end 2022.
Thailand's government, during COVID-19, provided medical supplies, including glucometers, blood glucose test strips, lancets, and urine test strips that were donated or purchased using donated funds. The supplies were stocked at a central location and distributed by volunteers, utilizing same-day commercial delivery services. Disposable prefilled insulin pens, both long-acting and short-acting analogs, were chosen instead of insulin vials to reduce administration errors, particularly in insulin-naïve patients. Insulin pens were kept at a medical clinic and distributed in a temperature-controlled container by a same-day delivery service.
Insulin therapy is the most potent hypoglycaemic medication currently available for diabetes treatment; however, the potency of insulin deteriorates if it is stored under improper conditions. In Thailand, NCDs, including diabetes, account for more than 70% of all deaths. Obesity leads to a more than seven times increase in the risk of developing type 2 diabetes, while being overweight increases the risk by three times.
Through Thailand's government encouragement, the usage of Management Devices increased over the forecast period.
Increasing Diabetes population in Thailand
The World Health Organization (WHO) estimates that in 2021, around 11% of the total health expenditure in Thailand is allocated to diabetes care, comparable to other countries in the region. By 2030, this figure is expected to grow by 41%, effectively doubling the societal burden of diabetes. In Thailand, around 4.8 million people have diabetes, and only 272 endocrinologists (or specialists) are available. In Thailand, three out of five people with diabetes who receive care do not achieve the recommended treatment targets.
Thus, the above factors are expected to drive the market growth over the forecast period.
Thailand Diabetes Care Drugs Industry Overview
The diabetes drugs market is Semi consolidated, with few significant generic players. A few major players, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb, dominate the insulin drugs and Sglt-2 drugs market. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, players are tapping into new markets to increase their market shares, especially in emerging economies where the demand is very high compared to the supply.
Thailand Diabetes Care Drugs Market Leaders
-
Eli Lilly
-
Boehringer Ingelheim
-
Astrazeneca
-
Sanofi
-
NovoNordisk
*Disclaimer: Major Players sorted in no particular order
Thailand Diabetes Care Drugs Market News
- March 2023: Daewoong Pharmaceutical intends to expedite its expansion into the ASEAN countries. This will commence with the submission of NDA for Envlo in Indonesia, Philippines, and Thailand. Additionally, they have outlined their strategy to facilitate entry into other nations including China, Saudi Arabia, and Russia. Their goal is to establish a presence in 15 countries by 2025 and further expand to 50 countries by 2030, solidifying their position as the leading pharmaceutical company in the nation.
- August 2022: Google Launched AI Project in Thailand to screen for diabetic eye disease, to show Social benefits of AI technologies.
Thailand Diabetes Care Drugs Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Oral Anti-diabetic drugs
- 5.1.1 Biguanides
- 5.1.1.1 Metformin
- 5.1.2 Alpha-Glucosidase Inhibitors
- 5.1.2.1 Alpha-Glucosidase Inhibitors
- 5.1.3 Dopamine D2 receptor agonist
- 5.1.3.1 Bromocriptin
- 5.1.4 SGLT-2 inhibitors
- 5.1.4.1 Invokana (Canagliflozin)
- 5.1.4.2 Jardiance (Empagliflozin)
- 5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
- 5.1.4.4 Suglat (Ipragliflozin)
- 5.1.5 DPP-4 inhibitors
- 5.1.5.1 Onglyza (Saxagliptin)
- 5.1.5.2 Tradjenta (Linagliptin)
- 5.1.5.3 Vipidia/Nesina(Alogliptin)
- 5.1.5.4 Galvus (Vildagliptin)
- 5.1.6 Sulfonylureas
- 5.1.6.1 Sulfonylureas
- 5.1.7 Meglitinides
- 5.1.7.1 Meglitinides
-
5.2 Insulins
- 5.2.1 Basal or Long Acting Insulins
- 5.2.1.1 Lantus (Insulin Glargine)
- 5.2.1.2 Levemir (Insulin Detemir)
- 5.2.1.3 Toujeo (Insulin Glargine)
- 5.2.1.4 Tresiba (Insulin Degludec)
- 5.2.1.5 Basaglar (Insulin Glargine)
- 5.2.2 Bolus or Fast Acting Insulins
- 5.2.2.1 NovoRapid/Novolog (Insulin Aspart)
- 5.2.2.2 Humalog (Insulin Lispro)
- 5.2.2.3 Apidra (Insulin Glulisine)
- 5.2.3 Traditional Human Insulins
- 5.2.3.1 Novolin/Actrapid/Insulatard
- 5.2.3.2 Humulin
- 5.2.3.3 Insuman
- 5.2.4 Biosimilar Insulins
- 5.2.4.1 Insulin Glargine Biosimilars
- 5.2.4.2 Human Insulin Biosimilars
-
5.3 Combination drugs
- 5.3.1 Insulin combinations
- 5.3.1.1 NovoMix (Biphasic Insulin Aspart)
- 5.3.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
- 5.3.1.3 Xultophy (Insulin Degludec and Liraglutide)
- 5.3.2 Oral Combinations
- 5.3.2.1 Janumet (Sitagliptin and Metformin)
-
5.4 Non-Insulin Injectable drugs
- 5.4.1 GLP-1 receptor agonists
- 5.4.1.1 Victoza (Liraglutide)
- 5.4.1.2 Byetta (Exenatide)
- 5.4.1.3 Bydureon (Exenatide)
- 5.4.1.4 Trulicity (Dulaglutide)
- 5.4.1.5 Lyxumia (Lixisenatide)
- 5.4.2 Amylin Analogue
- 5.4.2.1 Symlin (Pramlintide)
6. MARKET INDICATORS
- 6.1 Type-1 Diabetic Population
- 6.2 Type-2 Diabetic Population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Takeda
- 7.1.2 Novo Nordisk
- 7.1.3 Pfizer
- 7.1.4 Eli Lilly
- 7.1.5 Janssen Pharmaceuticals
- 7.1.6 Astellas
- 7.1.7 Boehringer Ingelheim
- 7.1.8 Merck And Co.
- 7.1.9 AstraZeneca
- 7.1.10 Bristol Myers Squibb
- 7.1.11 Novartis
- 7.1.12 Sanofi
- *List Not Exhaustive
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityThailand Diabetes Care Drugs Industry Segmentation
Diabetes or diabetes mellitus describes a group of metabolic disorders characterized by a high blood sugar level in a person. With diabetes, the body either does not produce enough insulin or the body's cells do not respond properly to insulin, or both. Thailand's diabetes care drugs market witnessed usd 532 million in the current year and is anticipated to register a cagr of over 1% during the forecast period. Thailand's diabetes care drugs market is segmented into drugs (oral anti-diabetic drugs, insulin, non-insulin injectable drugs, and combination drugs). The report offers the market size in value terms in usd for all the abovementioned segments.
| Oral Anti-diabetic drugs | Biguanides | Metformin |
| Oral Anti-diabetic drugs | Alpha-Glucosidase Inhibitors | Alpha-Glucosidase Inhibitors |
| Oral Anti-diabetic drugs | Dopamine D2 receptor agonist | Bromocriptin |
| Oral Anti-diabetic drugs | SGLT-2 inhibitors | Invokana (Canagliflozin) |
| Jardiance (Empagliflozin) | ||
| Farxiga/Forxiga (Dapagliflozin) | ||
| Suglat (Ipragliflozin) | ||
| Oral Anti-diabetic drugs | DPP-4 inhibitors | Onglyza (Saxagliptin) |
| Tradjenta (Linagliptin) | ||
| Vipidia/Nesina(Alogliptin) | ||
| Galvus (Vildagliptin) | ||
| Oral Anti-diabetic drugs | Sulfonylureas | Sulfonylureas |
| Oral Anti-diabetic drugs | Meglitinides | Meglitinides |
| Insulins | Basal or Long Acting Insulins | Lantus (Insulin Glargine) |
| Levemir (Insulin Detemir) | ||
| Toujeo (Insulin Glargine) | ||
| Tresiba (Insulin Degludec) | ||
| Basaglar (Insulin Glargine) | ||
| Insulins | Bolus or Fast Acting Insulins | NovoRapid/Novolog (Insulin Aspart) |
| Humalog (Insulin Lispro) | ||
| Apidra (Insulin Glulisine) | ||
| Insulins | Traditional Human Insulins | Novolin/Actrapid/Insulatard |
| Humulin | ||
| Insuman | ||
| Insulins | Biosimilar Insulins | Insulin Glargine Biosimilars |
| Human Insulin Biosimilars | ||
| Combination drugs | Insulin combinations | NovoMix (Biphasic Insulin Aspart) |
| Ryzodeg (Insulin Degludec and Insulin Aspart) | ||
| Xultophy (Insulin Degludec and Liraglutide) | ||
| Combination drugs | Oral Combinations | Janumet (Sitagliptin and Metformin) |
| Non-Insulin Injectable drugs | GLP-1 receptor agonists | Victoza (Liraglutide) |
| Byetta (Exenatide) | ||
| Bydureon (Exenatide) | ||
| Trulicity (Dulaglutide) | ||
| Lyxumia (Lixisenatide) | ||
| Non-Insulin Injectable drugs | Amylin Analogue | Symlin (Pramlintide) |
Thailand Diabetes Care Drugs Market Research FAQs
How big is the Thailand Diabetes Care Drugs Market?
The Thailand Diabetes Care Drugs Market size is expected to reach USD 152.23 million in 2024 and grow at a CAGR of 3.80% to reach USD 173.23 million by 2029.
What is the current Thailand Diabetes Care Drugs Market size?
In 2024, the Thailand Diabetes Care Drugs Market size is expected to reach USD 152.23 million.
Who are the key players in Thailand Diabetes Care Drugs Market?
Eli Lilly, Boehringer Ingelheim, Astrazeneca, Sanofi and NovoNordisk are the major companies operating in the Thailand Diabetes Care Drugs Market.
What years does this Thailand Diabetes Care Drugs Market cover, and what was the market size in 2023?
In 2023, the Thailand Diabetes Care Drugs Market size was estimated at USD 146.45 million. The report covers the Thailand Diabetes Care Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Thailand Diabetes Care Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Thailand Diabetes Care Drugs Industry Report
Statistics for the 2024 Thailand Diabetes Care Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Thailand Diabetes Care Drugs analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
